A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
ConditionNSCLC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital
About this trial
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients must be ≥18 years.
Provision of fully informed consent prior to any study specific procedures.
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
Disqualifiers
None
Trial population
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Progression-free survival
Progression-free survival (PFS) is defined as the time from beginning of study treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy prior to progression.
Time frame
2 yearsSecondary outcomes
1
Central nervous system (CNS) progression-free survival
CNS PFS is defined as the time from beginning of study treatment until the date of objective progression of central nervous system or death (by any cause in the absence of CNS progression), regardless of whether the patient withdraws from study treatment or receives another anti-cancer therapy prior to progression.
Time frame
2 years2
Objective Response Rate
Defined as the number (%) of patients with response of Complete Response or Partial Response
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov